CONTEXT

Some nucleosides are currently employed as antiviral agents and it is known that they must be metabolized in their triphosphorylated form in order to exert an antiviral or anticancer inhibitory activity. In the context of antiviral treatments, notably in anti-HIV therapies, it is important to quantify and to target with specific antibodies these triphosphorylated forms of the nucleosides analogues. The production of antibodies using triphosphate nucleoside molecules directly as hapten is a difficult task, because the phosphodiester bonds of the hapten in the immunogen are rapidly hydrolysed by endogenous phosphatases. This invention relates to the use of a method allowing to overcome this difficulty